Response Genetics Prices 4.46M Offering at $1.20 per Share

Response Genetics, Inc.

, a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today it priced its previously announced underwritten public offering of 4,464,443 registered shares of its common stock, par value $0.01 per share, at a price of $1.20 per share. The Company plans to use the approximately $4,844,465 million in net proceeds of the offering for working capital and general corporate purposes. In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to an additional 669,666 shares of common stock from the Company to cover over-allotments, if any.  National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc.

, is serving as the sole underwriter of the offering. The offering is expected to be completed on December 18, 2013, subject to the satisfaction or waiver of customary closing conditions. The securities described above are being offered by the Company pursuant to an effective shelf registration statement, including a base prospectus, filed with the Securities and Exchange Commission (the "SEC") on Form S-3 (File No. 333-171266) on December 17, 2010, as amended. A final prospectus supplement describing the terms of the offering will be filed with the SEC.  Any offer will be made, if at all, only by means of a prospectus supplement and accompanying base prospectus forming a part of the effective registration statement.  Before investing, you should read the prospectus supplement and the accompanying base prospectus, and other documents that the Company has filed or will file with the SEC, for information about the Company and this offering. Copies of the prospectus supplement and the accompanying base prospectus may be obtained, when available, by contacting the underwriter at the following address: National Securities Corporation 410 Park Avenue, 14th Floor New York, NY 10022 Attn: Kim Addarich Telephone: (212)-417-8164 Email: prospectusrequest@nationalsecurities.com This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Response Genetics, Inc. Response Genetics, Inc. is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.  The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens.  The Company's principal customers include oncologists and pathologists.  In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry.  The Company's headquarters is located in Los Angeles, California.